目的：探讨野生型 p53 诱导的磷酸酶 1（wild-type p53-induced phosphatase 1，Wip1）在小细胞肺癌（small-cell lung cancer，SCLC）细胞及血清中的表达及其与临床预后的关系。方法：采用实时荧光定量PCR（qPCR）法检测SCLC细胞及血清标本中Wip1的表达，分析其表达的临床意义。结果：Wip1在SCLC耐药细胞H69R中的表达较敏感细胞H69明显增加（P<0.01）。Wip1在SCLC血清中的表达较正常对照组明显升高（P<0.05）；且Wip1 在化疗耐药患者血清中的表达较化疗敏感者者明显升高（P<0.05）；血清中Wip1表达与SCLC患者的疾病分期、化疗敏感性及患者的生存状态关联（均P<0.05）。血清Wip1水平预测SCLC化疗疗效的ROC曲线下面积为0.836（95%CI：0.8230～0.9600，P<0.01）；Wip1的表达与SCLC患者的无进展生存时间及总生存时间明显关联（均P<0.05）。疾病分期、化疗敏感性及血清Wip水平是SCLC患者预后的独立影响因素（均P<0.05）。结论：SCLC患者血清中Wip1的表达可能与化疗敏感性及患者预后有关，Wip1可能是SCLC患者潜在的疗效及预后评估的生物标志物。

Objective: To investigate the expression of wild type p53 induced phosphatase 1 (Wip1) in small cell lung cancer (SCLC) cells and the serum of SCLC patient and its relationship with clinical prognosis. Methods: Real time quantitative PCR (qPCR) was used to detect the expression of Wip1 in SCLC cells and serum samples. Results: The expression of Wip1 in drug-resistant SCLC cells was significantly higher than that in sensitive cell lines (P<0.01). The expression of Wip1 in serum of SCLC group was significantly higher than that of normal control group (P<0.05); the expression of Wip1 in serum of patients with chemotherapy resistance was significantly higher than that in patients with chemotherapy sensitivity (all P<0.05); the serum Wip1 level was correlated with disease stage, chemotherapy sensitivity and survival status of SCLC patients (all P<0.05). The area under ROC curve of Wip1 predicting the prognosis of SCLC was 0.836 (95%CI: 0.8230-0.9600, P<0.01); the expression lever of Wip1 was significantly correlated with progression free survival and overall survival time of SCLC patients (all P<0.05). Disease stage, chemosensitivity and Wip1 expression were independent prognostic factors for SCLC patients (all P<0.05). Conclusion: The expression of Wip1 in serum of SCLC patients may be related to chemotherapy sensitivity and prognosis. Wip1 may be a potential biomarker for therapeutic efficacy and prognosis evaluation of SCLC patients.

四川省科技创新创业苗子工程项目（No. 2020087）